Gedatolisib (WYE-129587/PKI-587/PF-05212384; Figure 7), a PI3Kα/mTOR inhibitor, has been investigated in preclinical leukemia models, including T-ALL and Ph-like ALL, with very good results [160,161]. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.